AI May Improve Breast Mitotic Scoring - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

AI May Improve Breast Mitotic Scoring

Junior pathologists showed higher mitotic score accuracy and agreement with artificial intelligence assistance in a preliminary single-center reader study

  • By

  • Andrea Surnit

  • May 13, 2026

  • 4 min

Share

Objective:

To evaluate the effectiveness of an AI tool in enhancing mitotic score accuracy and reproducibility among junior pathologists assessing breast carcinoma whole-slide images.

Key Findings:
  • Mitotic score accuracy improved from 62% to 76% and from 64% to 78% with AI assistance for the two junior pathologists.
  • Weighted Cohen’s kappa increased significantly, indicating improved agreement with expert consensus.
  • The AI tool enhanced consistency in hotspot selection, with the proportion of AI-suggested hotspots intersecting selected counting zones increasing from 46% to 80%.
Interpretation:

AI assistance notably improved mitotic score accuracy, particularly in diagnostically challenging cases, while maintaining pathologists' autonomy in scoring.

Limitations:
  • The study involved only two junior pathologists at a single institution.
  • Specimens were retrospectively collected and evaluated in a structured setting, not during active clinical workflow.
Conclusion:

The AI tool demonstrated promise in improving mitotic scoring accuracy and consistency, warranting further investigation in broader clinical settings.

Original Source(s)

AI May Improve Breast Mitotic Scoring

  • by Andrea Surnit

  • May 13, 2026

Related Content

Does Structured Reporting Improve Lung Cancer Reports?

A structured reporting tool improved report completeness, reduced classification errors, and achieved high physician adoption during routine lung cancer pathology reporting.

Folate Biomarkers Linked to Lung Cancer

Cross-sectional NHANES analysis found associations between select folate markers and self-reported physician-diagnosed lung cancer, though the direction and clinical significance of the relationship remain unclear

FDA approves serial liquid biopsy testing

In SERENA-6, patients who changed treatment following detection of an ESR1 mutation had a 56% lower risk of disease progression or death.